{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:57:57Z","timestamp":1793858277303,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72985-6","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:59:25Z","timestamp":1784797165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1\/2 trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Eric S.","family":"Christenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah A.","family":"Wala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-9244","authenticated-orcid":false,"given":"Natalie B.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1085-2157","authenticated-orcid":false,"given":"Christopher","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-7705","authenticated-orcid":false,"given":"Jia-Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5016-0112","authenticated-orcid":false,"given":"Kristin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-6940","authenticated-orcid":false,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-5086","authenticated-orcid":false,"given":"Won Jin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kulikowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Cetasaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Meyerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2110-7697","authenticated-orcid":false,"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-3278","authenticated-orcid":false,"given":"Benjamin L.","family":"Schlechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene","family":"Browner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-2541","authenticated-orcid":false,"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-2013","authenticated-orcid":false,"given":"Harshabad","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Donehower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-6549","authenticated-orcid":false,"given":"Elizabeth M.","family":"Jaffee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-1838","authenticated-orcid":false,"given":"Peter K.","family":"Sorger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-6982","authenticated-orcid":false,"given":"Marios","family":"Giannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"72985_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"72985_CR2","first-page":"145","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L. et al. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70, 145\u2013164 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"72985_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"72985_CR4","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/1078-0432.CCR-13-0027","volume":"19","author":"K Ng","year":"2013","unstructured":"Ng, K. et al. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin. Cancer Res. 19, 3987\u20133995 (2013).","journal-title":"Clin. Cancer Res."},{"key":"72985_CR5","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","volume":"406","author":"JR Hecht","year":"2025","unstructured":"Hecht, J. R. et al. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet 406, 2360\u20132370 (2025).","journal-title":"Lancet"},{"key":"72985_CR6","doi-asserted-by":"publisher","unstructured":"Tan, P. B. et al. Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers. Nature https:\/\/doi.org\/10.1038\/s41586-025-09679-4 (2025).","DOI":"10.1038\/s41586-025-09679-4"},{"key":"72985_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fonc.2014.00035","volume":"4","author":"G Cathomas","year":"2014","unstructured":"Cathomas, G. PIK3CA in colorectal cancer. Front. Oncol. 4, 35 (2014).","journal-title":"Front. Oncol."},{"key":"72985_CR8","doi-asserted-by":"publisher","first-page":"e003402","DOI":"10.1136\/jitc-2021-003402","volume":"10","author":"NB Collins","year":"2022","unstructured":"Collins, N. B. et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J. Immunother. Cancer 10, e003402 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"72985_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","volume":"31","author":"K Okkenhaug","year":"2013","unstructured":"Okkenhaug, K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31, 675\u2013704 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"72985_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2174\/1568009617666170927114440","volume":"18","author":"DC Collins","year":"2018","unstructured":"Collins, D. C., Chenard-Poirier, M. & Lopez, J. S. The PI3K pathway at the crossroads of cancer and the immune system: strategies for next generation immunotherapy combinations. Curr. Cancer Drug Targets 18, 355\u2013364 (2018).","journal-title":"Curr. Cancer Drug Targets"},{"key":"72985_CR11","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72985_CR12","first-page":"1003","volume":"42","author":"D Juric","year":"2024","unstructured":"Juric, D. et al. First-line inavolisib\/placebo + palbociclib + fulvestrant (Inavo\/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced\/metastatic breast cancer who relapsed during\/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. J. Clin. Orthod. 42, 1003\u20131003 (2024).","journal-title":"J. Clin. Orthod."},{"key":"72985_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s11523-017-0530-5","volume":"12","author":"ZA Wainberg","year":"2017","unstructured":"Wainberg, Z. A. et al. A multi-arm phase I study of the PI3K\/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced cancer. Target. Oncol. 12, 775\u2013785 (2017).","journal-title":"Target. Oncol."},{"key":"72985_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","volume":"21","author":"D Sarker","year":"2015","unstructured":"Sarker, D. et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 21, 77\u201386 (2015).","journal-title":"Clin. Cancer Res."},{"key":"72985_CR15","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine\u2013Tipiracil and Bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"72985_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"72985_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402, 41\u201353 (2023).","journal-title":"Lancet"},{"key":"72985_CR18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).","journal-title":"Science"},{"key":"72985_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1483","volume":"13","author":"X Li","year":"2023","unstructured":"Li, X. et al. Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5-lipoxygenase-dependent arachidonic acid pathway. Clin. Transl. Med. 13, e1483 (2023).","journal-title":"Clin. Transl. Med."},{"key":"72985_CR20","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","volume":"12","author":"N Liu","year":"2013","unstructured":"Liu, N. et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 12, 2319\u20132330 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"72985_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s40425-018-0457-0","volume":"6","author":"LS Carnevalli","year":"2018","unstructured":"Carnevalli, L. S. et al. PI3K\u03b1\/\u03b4 inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. J. Immunother Cancer 6, 158 (2018).","journal-title":"J. Immunother Cancer"},{"key":"72985_CR22","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1007\/s10238-023-01227-6","volume":"23","author":"S Heller","year":"2023","unstructured":"Heller, S. et al. Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses. Clin. Exp. Med. 23, 5445\u20135461 (2023).","journal-title":"Clin. Exp. Med."},{"key":"72985_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2217\/pgs.15.174","volume":"17","author":"LW Cheung","year":"2016","unstructured":"Cheung, L. W. & Mills, G. B. Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. Pharmacogenomics 17, 297\u2013307 (2016).","journal-title":"Pharmacogenomics"},{"key":"72985_CR24","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"72985_CR25","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1200\/JCO.21.01648","volume":"40","author":"S Damodaran","year":"2022","unstructured":"Damodaran, S. et al. Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F. J. Clin. Oncol. 40, 1552\u20131561 (2022).","journal-title":"J. Clin. Oncol."},{"key":"72985_CR26","doi-asserted-by":"publisher","first-page":"113437","DOI":"10.1016\/j.ejca.2023.113437","volume":"196","author":"M Fakih","year":"2024","unstructured":"Fakih, M. et al. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases. Eur. J. Cancer 196, 113437 (2024).","journal-title":"Eur. J. Cancer"},{"key":"72985_CR27","first-page":"15","volume":"40","author":"A Barzi","year":"2022","unstructured":"Barzi, A. et al. Phase I\/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC). J. Clin. Orthod. 40, 15\u201315 (2022).","journal-title":"J. Clin. Orthod."},{"key":"72985_CR28","first-page":"LBA8","volume":"41","author":"AB El-Khoueiry","year":"2023","unstructured":"El-Khoueiry, A. B. et al. Results from a phase 1a\/1b study of botensilimab (BOT), a novel innate\/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). J. Clin. Orthod 41, LBA8\u2013LBA8 (2023).","journal-title":"J. Clin. Orthod"},{"key":"72985_CR29","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s43018-023-00576-1","volume":"4","author":"J-R Lin","year":"2023","unstructured":"Lin, J.-R. et al. High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers. Nat. Cancer 4, 1036\u20131052 (2023).","journal-title":"Nat. Cancer"},{"key":"72985_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-51889-9","volume":"14","author":"N Singla","year":"2024","unstructured":"Singla, N. et al. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. Sci. Rep. 14, 1458 (2024).","journal-title":"Sci. Rep."},{"key":"72985_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72985_CR32","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.molmed.2016.10.002","volume":"22","author":"HE Ghoneim","year":"2016","unstructured":"Ghoneim, H. E., Zamora, A. E., Thomas, P. G. & Youngblood, B. A. Cell-intrinsic barriers of T cell-based immunotherapy. Trends Mol. Med. 22, 1000\u20131011 (2016).","journal-title":"Trends Mol. Med."},{"key":"72985_CR33","doi-asserted-by":"publisher","first-page":"e31657","DOI":"10.7554\/eLife.31657","volume":"7","author":"J-R Lin","year":"2018","unstructured":"Lin, J.-R. et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife 7, e31657 (2018).","journal-title":"Elife"},{"key":"72985_CR34","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.3390\/ijms221910260","volume":"22","author":"C Stefani","year":"2021","unstructured":"Stefani, C. et al. Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now?Int. J. Mol. Sci. 22, 10260 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"72985_CR35","doi-asserted-by":"publisher","first-page":"7555","DOI":"10.1200\/JCO.2023.41.16_suppl.7555","volume":"41","author":"MH Dreyling","year":"2023","unstructured":"Dreyling, M. H. et al. Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma. J. Clin. Oncol. 41, 7555\u20137555 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72985_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"72985_CR37","doi-asserted-by":"crossref","unstructured":"Bullock, A. J. & Sanborn, R. E. Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Ann. Oncol. 34, S178\u2013S179 (2023).","DOI":"10.1016\/j.annonc.2023.04.014"},{"key":"72985_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152\u2013164 (2021).","journal-title":"Nat. Med."},{"key":"72985_CR39","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.eclinm.2023.101917","volume":"58","author":"M Fakih","year":"2023","unstructured":"Fakih, M. et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine 58, 101917 (2023).","journal-title":"EClinicalMedicine"},{"key":"72985_CR40","doi-asserted-by":"publisher","unstructured":"Christenson, E. S. et al. Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0002. (2025).","DOI":"10.1158\/1078-0432.CCR-25-0002"},{"key":"72985_CR41","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.cels.2018.05.004","volume":"6","author":"S Sampattavanich","year":"2018","unstructured":"Sampattavanich, S. et al. Encoding growth factor identity in the temporal dynamics of FOXO3 under the combinatorial control of ERK and AKT kinases. Cell Syst. 6, 664\u2013678.e9 (2018).","journal-title":"Cell Syst."},{"key":"72985_CR42","doi-asserted-by":"publisher","first-page":"26089","DOI":"10.1074\/jbc.M504045200","volume":"280","author":"MK Holz","year":"2005","unstructured":"Holz, M. K. & Blenis, J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280, 26089\u201326093 (2005).","journal-title":"J. Biol. Chem."},{"key":"72985_CR43","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S. et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer. N. Engl. J. Med. 381, 1632\u20131643 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72985_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S1470-2045(21)00652-5","volume":"23","author":"P Pfeiffer","year":"2022","unstructured":"Pfeiffer, P. & Qvortrup, C. KRASG12C inhibition in colorectal cancer. Lancet Oncol. 23, 10\u201311 (2022).","journal-title":"Lancet Oncol."},{"key":"72985_CR45","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"72985_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00055","volume":"3","author":"S Chakrabarti","year":"2019","unstructured":"Chakrabarti, S. et al. Intratumoral CD3+ and CD8+ T-cell densities in patients with DNA mismatch repair-deficient metastatic colorectal cancer receiving programmed cell death-1 blockade. JCO Precis. Oncol. 3, 1\u20137 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"72985_CR47","doi-asserted-by":"publisher","unstructured":"Vilain, R. E. et al. Supplementary notes and Supplementary Figs. 1 and 2 from dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. https:\/\/doi.org\/10.1158\/1078-0432.22466867.v1. (2023).","DOI":"10.1158\/1078-0432.22466867.v1"},{"key":"72985_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).","journal-title":"Nat. Commun."},{"key":"72985_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41592-021-01308-y","volume":"19","author":"D Schapiro","year":"2022","unstructured":"Schapiro, D. et al. MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Nat. Methods 19, 311\u2013315 (2022).","journal-title":"Nat. Methods"},{"key":"72985_CR50","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1038\/s41596-019-0206-y","volume":"14","author":"Z Du","year":"2019","unstructured":"Du, Z. et al. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nat. Protoc. 14, 2900\u20132930 (2019).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72985-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72985-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72985-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:59:31Z","timestamp":1784797171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72985-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72985"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72985-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding and material support for the study were provided by Bayer and Bristol-Myers-Squibb (BMS). Azad and Le are paid advisory board members to Bristol-Myers-Squibb. Azad and Le received grant funding from Bayer and Bristol-Myers-Squibb. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict-of-interest policies. Schlechter serves on the advisory board of Agenus. Giannakis receives research funding from Janssen and Sunbird Bio, and has received consulting fees from Nerviano Medical Sciences and honoraria from PER and OncLive, all unrelated to this work. Wala has received consulting fees from Bullfrog AI, Echo Immunotherapeutics, and Medzown unrelated to this work. Sorger is a Founder and member of the BOD of Glencoe Software, a member of SAB for RareCyte, Reverb Therapeutics, and Montai Health, and consults for Merck unrelated to this work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7114"}}